152 related articles for article (PubMed ID: 22133477)
1. Impact of complications and comorbidities on treatment costs and health-related quality of life of patients with Parkinson's disease.
Bach JP; Riedel O; Klotsche J; Spottke A; Dodel R; Wittchen HU
J Neurol Sci; 2012 Mar; 314(1-2):41-7. PubMed ID: 22133477
[TBL] [Abstract][Full Text] [Related]
2. Trends in resource utilization for Parkinson's disease in Germany.
Winter Y; Balzer-Geldsetzer M; von Campenhausen S; Spottke A; Eggert K; Oertel WH; Dodel R
J Neurol Sci; 2010 Jul; 294(1-2):18-22. PubMed ID: 20493500
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
[TBL] [Abstract][Full Text] [Related]
4. Costs of drug treatment in Parkinson's disease.
Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
[TBL] [Abstract][Full Text] [Related]
5. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
Cubo E; Martínez Martin P; González M; Frades B;
Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
[TBL] [Abstract][Full Text] [Related]
6. Drug costs for patients with Parkinson's disease in two different European countries.
Vossius C; Gjerstad M; Baas H; Larsen JP
Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
[TBL] [Abstract][Full Text] [Related]
7. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study.
Riedel O; Heuser I; Klotsche J; Dodel R; Wittchen HU;
J Geriatr Psychiatry Neurol; 2010 Mar; 23(1):27-34. PubMed ID: 20042544
[TBL] [Abstract][Full Text] [Related]
8. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
[TBL] [Abstract][Full Text] [Related]
9. Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: results from Chinese L-dopa exposed cohort.
Qin Z; Zhang L; Sun F; Liu H; Fang X; Chan P;
Clin Neurol Neurosurg; 2009 Nov; 111(9):733-7. PubMed ID: 19665835
[TBL] [Abstract][Full Text] [Related]
10. [Parkinson's disease: cost-of-illness in an outpatient cohort].
Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
[TBL] [Abstract][Full Text] [Related]
11. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
12. Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset.
Diederich NJ; Moore CG; Leurgans SE; Chmura TA; Goetz CG
Arch Neurol; 2003 Apr; 60(4):529-33. PubMed ID: 12707066
[TBL] [Abstract][Full Text] [Related]
13. Application of depression criteria (DSM-IV) in patients with Parkinson's disease.
Gómez-Esteban JC; Tijero B; Somme J; Bilbao I; Fernández J; Boyero S; Velasco F; Lezcano E; Zarranz JJ
Clin Neurol Neurosurg; 2009 Oct; 111(8):665-9. PubMed ID: 19589638
[TBL] [Abstract][Full Text] [Related]
14. The economic impact of cognitive impairment in Parkinson's disease.
Vossius C; Larsen JP; Janvin C; Aarsland D
Mov Disord; 2011 Jul; 26(8):1541-4. PubMed ID: 21538519
[TBL] [Abstract][Full Text] [Related]
15. Drug and treatment costs in Parkinson's disease patients in Sweden.
Lökk J; Borg S; Svensson J; Persson U; Ljunggren G
Acta Neurol Scand; 2012 Feb; 125(2):142-7. PubMed ID: 21470194
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
Chen JJ
Am J Manag Care; 2010 Mar; 16 Suppl Implications():S87-93. PubMed ID: 20297871
[TBL] [Abstract][Full Text] [Related]
17. Anxiety disorders in Parkinson's disease: prevalence and risk factors.
Dissanayaka NN; Sellbach A; Matheson S; O'Sullivan JD; Silburn PA; Byrne GJ; Marsh R; Mellick GD
Mov Disord; 2010 May; 25(7):838-45. PubMed ID: 20461800
[TBL] [Abstract][Full Text] [Related]
18. The health burdens of Parkinson's disease.
Chrischilles EA; Rubenstein LM; Voelker MD; Wallace RB; Rodnitzky RL
Mov Disord; 1998 May; 13(3):406-13. PubMed ID: 9613729
[TBL] [Abstract][Full Text] [Related]
19. A comparison of health-care costs involved in treating people with and without Parkinson's disease in Southern Sydney, New South Wales, Australia.
Cordato DJ; Schwartz R; Abbott E; Saunders R; Morfis L
J Clin Neurosci; 2006 Jul; 13(6):655-8. PubMed ID: 16797991
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
